GBM tumors are highly resistant to current therapies, and increasing evidence shows the role of activated WNT/β-catenin, PI3K/mTOR, and RAS signaling in GBM progression and recurrence (99–102). This evidence concerns the gene PIK3CA and glioblastoma.